Clinical Trial Update: A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II randomized, placebo-controlled study evaluating KD018 as a modulator of irinotecan in metastatic colorectal cancer; study completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• KD018

Snippet

Sponsor: Edward Chu, MD | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2019-05-22